Larson Financial Group
AVBP icon

Larson Financial Group’s ArriVent BioPharma AVBP Stock Holding History

Larson Financial Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.66K Buy
286
+9
+3% +$276 ﹤0.01% 2580
2026
Q2 		$9.6K Hold
277
– – ﹤0.01% 2434
2026
Q1 		$6.39K Sell
277
-191
-41% -$4.31K ﹤0.01% 2481
2025
Q4 		$9.42K Buy
468
+454
+3,243% +$9.45K ﹤0.01% 2147
2025
Q3 		$258 Buy
+14
New +$275 ﹤0.01% 3223

Other funds holding AVBP

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HSG Holding
HSG Holding Na, Hong Kong $1.26B AUM 34.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Larson Financial Group's AVBP Position: Q3 2026 in Review

Larson Financial Group increased its ArriVent BioPharma (AVBP) stake by 3.2% in Q3 2026, buying an estimated $276 and bringing the position to 286 shares worth $8.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Larson Financial Group first reported a position in AVBP in Q3 2025 and has held it in 5 quarters since. The position peaked at $9.6K in Q2 2026. 96 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Larson Financial Group held 286 shares of ArriVent BioPharma worth $8.66K as of Q3 2026.
  • Larson Financial Group bought 9 ArriVent BioPharma shares in Q3 2026, an estimated $276.
  • ArriVent BioPharma made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2580 holding.
  • Larson Financial Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 5 quarters since.
  • Larson Financial Group's ArriVent BioPharma position peaked at $9.6K in Q2 2026.
  • 96 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.